NO20062810L - Fast farmasoytisk preparatform - Google Patents

Fast farmasoytisk preparatform

Info

Publication number
NO20062810L
NO20062810L NO20062810A NO20062810A NO20062810L NO 20062810 L NO20062810 L NO 20062810L NO 20062810 A NO20062810 A NO 20062810A NO 20062810 A NO20062810 A NO 20062810A NO 20062810 L NO20062810 L NO 20062810L
Authority
NO
Norway
Prior art keywords
solid pharmaceutical
pharmaceutical form
preparation
relates
disorders
Prior art date
Application number
NO20062810A
Other languages
English (en)
Inventor
Ulrich Brauns
Thomas Friedl
Sabine Landerer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10353832A external-priority patent/DE10353832A1/de
Priority claimed from DE102004012045A external-priority patent/DE102004012045A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20062810L publication Critical patent/NO20062810L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Oppfinnelsen angår en fast farmasøytisk preparatform inneholdende ett eller flere tilsetningsmidler og/eller adjuvanser og en aktiv substans fra gruppen bestående av monoamin-neurotransmitter reopptaks-inhibitorer som har en 2,3-disubstituert tropan-struktur. Oppfinnelsen angår også fremstilling av denne preparatform og anvendelse derav for fremstilling av et medikament for behandling eller forebygging av sentralnervesystem-lidelser eller forstyrrelser.
NO20062810A 2003-11-18 2006-06-15 Fast farmasoytisk preparatform NO20062810L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10353832A DE10353832A1 (de) 2003-11-18 2003-11-18 Feste pharmazeutische Zubereitungsform
DE102004012045A DE102004012045A1 (de) 2004-03-11 2004-03-11 Feste pharmazeutische Zubereitungsform
PCT/EP2004/012683 WO2005049024A2 (de) 2003-11-18 2004-11-10 Feste pharmazeutische zubereitungsform

Publications (1)

Publication Number Publication Date
NO20062810L true NO20062810L (no) 2006-08-10

Family

ID=34621295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062810A NO20062810L (no) 2003-11-18 2006-06-15 Fast farmasoytisk preparatform

Country Status (18)

Country Link
US (2) US20050124651A1 (no)
EP (1) EP1686965A2 (no)
JP (2) JP2007511559A (no)
KR (1) KR20060125805A (no)
AR (1) AR046709A1 (no)
AU (1) AU2004290520A1 (no)
BR (1) BRPI0416691A (no)
CA (1) CA2545513C (no)
CO (1) CO5690555A2 (no)
HK (1) HK1094676A1 (no)
IL (1) IL175246A0 (no)
MX (1) MXPA06005545A (no)
NO (1) NO20062810L (no)
NZ (1) NZ547880A (no)
PE (1) PE20050479A1 (no)
RU (1) RU2377987C2 (no)
TW (1) TW200529844A (no)
WO (1) WO2005049024A2 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06005545A (es) * 2003-11-18 2006-08-17 Boehringer Ingelheim Int Preparacion farmaceutica solida.
WO2007028769A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitor for neuroprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227524A (ja) * 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
JPS62221626A (ja) * 1986-03-20 1987-09-29 Tokyo Tanabe Co Ltd １，４−ジヒドロピリジン化合物の製剤用組成物
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
JPH07118154A (ja) * 1993-10-22 1995-05-09 Dainippon Pharmaceut Co Ltd 固体分散体および粒状製剤
EE04751B1 (et) * 1996-02-22 2006-12-15 Neurosearch A/S Tropaani derivaadid, nende valmistamine ja kasutamine
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
DK1267880T4 (da) * 2000-02-29 2010-05-17 Bristol Myers Squibb Co Entecavir-formulering med lav dosis og anvendelse deraf
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
US20040106643A1 (en) * 2001-05-23 2004-06-03 Gouliaev Alex Haarh Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DE60216142T2 (de) * 2001-11-30 2007-09-06 Neurosearch A/S Tropan-Derivate mit einer die Wiederaufnahme von Dopamin hemmenden Aktivität zur Behandlung von ischämischen Erkrankungen
US7459464B2 (en) * 2002-05-30 2008-12-02 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
CA2542442C (en) * 2003-10-16 2012-08-21 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
MXPA06005545A (es) * 2003-11-18 2006-08-17 Boehringer Ingelheim Int Preparacion farmaceutica solida.
CA2554617A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist

Also Published As

Publication number Publication date
BRPI0416691A (pt) 2007-01-30
AU2004290520A1 (en) 2005-06-02
CA2545513A1 (en) 2005-06-02
WO2005049024A3 (de) 2006-03-30
MXPA06005545A (es) 2006-08-17
EP1686965A2 (de) 2006-08-09
RU2006121446A (ru) 2008-01-10
US20100178342A1 (en) 2010-07-15
RU2377987C2 (ru) 2010-01-10
US20050124651A1 (en) 2005-06-09
JP2007511559A (ja) 2007-05-10
HK1094676A1 (en) 2007-04-04
WO2005049024A2 (de) 2005-06-02
KR20060125805A (ko) 2006-12-06
TW200529844A (en) 2005-09-16
NZ547880A (en) 2010-02-26
AR046709A1 (es) 2005-12-21
PE20050479A1 (es) 2005-10-06
CO5690555A2 (es) 2006-10-31
IL175246A0 (en) 2006-10-31
CA2545513C (en) 2013-01-08
JP2011068690A (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
NO20045072L (no) Tablett med hoyt medikamentinnhold
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
NO20055219L (no) Nye forbindelser
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
NO20050828L (no) lndol-3-svovelderivater
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20071314L (no) Peptidiske vasopressinreseptoragonister
SE0302760D0 (sv) New compounds
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
DK2035375T3 (da) 1,3 Disubstituerede 4-methyl-1H pyrrol-2-carboxamider og deres anvendelse til fremstilling af lægemidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application